ID: ALA5291034

Max Phase: Preclinical

Molecular Formula: C21H19N7O

Molecular Weight: 385.43

Representations

Canonical SMILES:  C=CC(=O)N1CC[C@@H](n2nc(-c3cnc4ccccc4c3)c3c(N)ncnc32)C1

Standard InChI:  InChI=1S/C21H19N7O/c1-2-17(29)27-8-7-15(11-27)28-21-18(20(22)24-12-25-21)19(26-28)14-9-13-5-3-4-6-16(13)23-10-14/h2-6,9-10,12,15H,1,7-8,11H2,(H2,22,24,25)/t15-/m1/s1

Standard InChI Key:  SJLAAMAKAKHNLF-OAHLLOKOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 385.43

Molecular Weight (Monoisotopic): 385.1651

AlogP: 2.58

#Rotatable Bonds: 3

Polar Surface Area: 102.82

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 4.14

CX LogP: 1.77

CX LogD: 1.77

Aromatic Rings: 4

Heavy Atoms: 29

QED Weighted: 0.54

Np Likeness Score: -1.00

References

1. Ito S, Otsuki S, Ohsawa H, Hirano A, Kazuno H, Yamashita S, Egami K, Shibata Y, Yamamiya I, Yamashita F, Kodama Y, Funabashi K, Kazuno H, Komori T, Suzuki S, Sootome H, Hirai H, Sagara T..  (2023)  Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.,  14  (4): [PMID:37077386] [10.1021/acsmedchemlett.3c00006]

Source

Source(1):

• Scientific Literature